Insulin Resistance: What It Means, How It Is Measured and What Actually Helps

Insulin resistance means that a tissue or the body responds less to a given amount of insulin. It is not the same as prediabetes, it cannot be diagnosed from fatigue or cravings, and it has no single universal number. The useful clinical question is not simply “Do I have it?” It is whether a persistent cardiometabolic pattern is present, which cause or condition accompanies it, and which result would change a decision.

Glucose can remain normal for a time because the pancreas compensates by producing more insulin. Insulin sensitivity also changes physiologically during pregnancy, acute illness, sleep disruption, fasting and exercise. A fasting insulin, HOMA-IR score or CGM spike should therefore never become a stand-alone diagnosis.

What insulin resistance actually means

Insulin is not one identical key throughout the body. In muscle it supports glucose uptake; in the liver it helps suppress glucose production; in adipose tissue it restrains fatty-acid release. The joint 2026 ADA/EASD review frames insulin resistance as a dynamic, graded and tissue-specific phenotype, not one uniform disease.

Tissue or system	What may happen	What may appear clinically
Muscle	Less insulin-stimulated glucose uptake	Higher post-meal glucose, lower fitness or adiposity, although none is specific
Liver	Insulin suppresses hepatic glucose production less effectively	Fasting glucose, triglycerides or MASLD may rise
Adipose tissue	Lipolysis is less suppressed and fatty-acid flux rises	Visceral fat, ectopic lipid and an adverse metabolic pattern
Pancreas	It compensates with more insulin until reserve is insufficient	Normal glucose early; prediabetes or diabetes if compensation fails

The same person may respond differently in liver, muscle and fat. A normal fasting result may not fully describe the response after food. Conversely, a temporary reduction in sensitivity during infection, pregnancy or after a very short night is not automatically chronic metabolic disease.

Symptoms: why the body does not provide a diagnostic checklist

Insulin resistance and prediabetes are usually silent. Marked thirst, frequent urination, blurred vision, repeated infections or unexplained weight loss suggest hyperglycaemia and call for glucose testing; they are not specific early insulin-resistance symptoms.

Acanthosis nigricans—darkened, thick, velvety skin, often on the neck or underarms—may accompany hyperinsulinaemia. PCOS, MASLD, obstructive sleep apnoea, visceral obesity, high triglycerides with low HDL, previous gestational diabetes, family history or unexpectedly high insulin requirements also raise suspicion. None shows exactly how one tissue responds to insulin.

Medication review should include glucocorticoids, some antipsychotics and selected HIV treatments. Cushing syndrome, acromegaly and rarer conditions sometimes matter. The aim is not to blame weight or explain every symptom through metabolism; it is to find treatable contributors and cumulative risk.

At what age does it appear?

There is no single age. Insulin resistance can occur in childhood and adolescence, particularly with obesity, family history, acanthosis or PCOS. Sensitivity falls physiologically during puberty and usually recovers afterwards; pregnancy also requires a temporary adaptation. In adulthood, risk often rises with visceral adiposity, less muscle mass or activity, insufficient sleep, menopause, apnoea, MASLD, selected medicines and age. Age modifies risk but does not make a diagnosis.

The 2026 ADA Standards recommend screening every adult for prediabetes and diabetes from age 35. Testing begins earlier when overweight or obesity is accompanied by at least one risk factor. In children and adolescents with overweight or obesity plus added risk, screening starts after puberty begins or at age 10, whichever comes first. These are ages for validated glucose testing; they do not mean resistance begins at 35 or that everyone needs HOMA-IR.

How to know if you have insulin resistance: what each test measures

Test	Question answered	Clinical value	Main limitation
Fasting plasma glucose	Glucose after at least 8 hours without calories	Diagnoses prediabetes and diabetes using validated criteria	One snapshot; may miss post-meal dysglycaemia
A1C	Approximate average glucose exposure over 2–3 months	No fast required; used for diagnosis and follow-up	Anaemia, haemoglobin variants, pregnancy and red-cell turnover may distort it
75-g OGTT	Fasting and 2-hour glucose after a challenge	Finds impaired tolerance that other tests may miss	Time, preparation and variability; insulin curves have no universal diagnostic cutoffs
Fasting insulin / HOMA-IR	Basal relationship between glucose and endogenous insulin	A surrogate for research and selected clinical questions	Depends on assay, secretion, clearance, kidney function, glycaemia and population
Matsuda, OGIS and dynamic indices	Glucose–insulin relationship during an OGTT	Closer to whole-body response than fasting indices	Different models, time points and populations; not standard routine diagnoses
TyG index	Combines fasting triglycerides and glucose without insulin	Accessible epidemiological proxy for group stratification	Does not directly measure tissue action or diagnose an individual
Hyperinsulinaemic–euglycaemic clamp	Glucose required to maintain euglycaemia under controlled insulin	Reference method for human insulin sensitivity	Complex, expensive and protocol-dependent; not a clinic screening test

Prediabetes is not the same as a high HOMA-IR

Outside pregnancy, prediabetes is defined by A1C 5.7–6.4%, fasting plasma glucose 100–125 mg/dL, or 2-hour OGTT glucose 140–199 mg/dL. Diabetes thresholds are A1C ≥6.5%, fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL; random glucose ≥200 mg/dL is diagnostic with classic symptoms. Unless hyperglycaemia is unequivocal, a result is confirmed.

These criteria classify glycaemia, not every aspect of insulin biology. One person may compensate with more insulin and remain normoglycaemic. Another may have high glucose because pancreatic secretion is now insufficient, making an insulin-based HOMA estimate less reliable.

HOMA-IR: an estimate, not a universal traffic light

The classic formula combines fasting glucose and insulin. It is easy to calculate, yet two assays may produce different insulin values from the same sample. Secretion, hepatic clearance, glycaemic state, medication, kidney function and the reference population also influence the score. HOMA2 uses an updated computer model without removing those limits.

In the 2026 expert forum, pooled correlation between log HOMA-IR and the clamp was −0.60; Matsuda and OGIS reached 0.67 and 0.70. These are useful group-level relationships, not equivalence to a direct measurement or a map of one organ.

The 2.93 cutoff: what the 2026 study established

A cross-sectional study assessed 665 people and included 515 White European adults with BMI ≥25 kg/m² and no diabetes; 80.9% were women and 40% met metabolic-syndrome criteria. With cross-validation, it proposed HOMA-IR >2.93 for identifying metabolic syndrome, with AUROC 0.663. Matsuda <3.33 reached 0.675 and HOMA2-IR >1.67 reached 0.651.

An AUROC of 0.663 is modest discrimination. The study was cross-sectional, selected people with overweight or obesity, excluded diabetes and used prevalent metabolic syndrome as its reference. It did not validate a universal threshold, predict future diabetes or show that screening or treating the number improves outcomes.

What to measure now—and when to repeat it

1. Define the question. Are there hyperglycaemia symptoms, family history, previous gestational diabetes, PCOS, MASLD, sleep apnoea, relevant medication, or changing waist and blood pressure?
2. Start with measures that change decisions. Blood pressure, waist and weight/body-composition trend; glucose, A1C and lipids; liver enzymes and other tests only when history supports them.
3. Use an OGTT when it resolves a discrepancy. It may add value when fasting glucose and A1C do not explain risk or after gestational diabetes. Adding insulin requires a plan for interpretation.
4. Avoid the infinite panel. HOMA, TyG, CGM, adiponectin and metabolomics do not become useful by accumulation. A biomarker deserves measurement when a result has an action rule.
5. Repeat on the right timescale. A1C reflects months, not one week. Prediabetes is generally monitored at least yearly; a normal result with risk is usually repeated within three years, sooner if risk changes. A treatment change may justify clinical and glucose review after 8–12 weeks.

When results conflict—for example, elevated A1C with repeatedly normal glucose—review anaemia, haemoglobin variants, kidney disease, medication and pre-analytical quality before creating a story about “hidden insulin”.

An 8–12 week plan that does not chase one number

This plan does not replace diabetes treatment or indicated medication. It is a discussion framework for a stable adult, with intensity adapted to capacity and comorbidity.

Weeks 0–2: build a small baseline

• Record waist, blood pressure, weekly activity, functional strength, sleep, medication and only the laboratory measures that answer the question.
• Choose two frequent meals to improve: more vegetables, pulses, whole grains, nuts, olive oil and a suitable protein source; fewer sugar-sweetened drinks and ultra-processed products. Our evidence-based eating guide avoids magic lists.
• If sitting dominates the day, stand and move briefly every 30–60 minutes. This does not erase sedentary exposure, but it interrupts it and makes the pattern visible.

Weeks 3–8: progress muscle, aerobic capacity and recovery

• Aerobic activity: progress toward 150 minutes per week at moderate intensity, across at least three days, when safe. Brisk walking, cycling, water-based movement or dancing can all contribute.
• Strength: add 2–3 weekly sessions using major muscle groups with tolerable progression. Muscle is important for glucose disposal, but function and independence are equally valid outcomes.
• Daily movement: add steps from your baseline and interrupt prolonged sitting. Our guide to moving again without turning it into another chore offers a gradual entry.
• Sleep: work toward regularity and sufficient opportunity; assess snoring, witnessed pauses, morning headache or daytime sleepiness. Sleep apnoea needs evaluation, not sleep-hygiene advice alone.
• Stress: identify what disrupts sleep, food choices, alcohol use or movement. Breathing practice, relaxation, time in nature, social support or psychotherapy may support regulation and adherence; evidence does not justify promising that “lowering cortisol” alone reverses resistance.
• Weight, when relevant: in high-risk people with overweight or obesity, sustained loss of 5–7% reduced diabetes progression in the DPP. It is not a universal requirement or a test of willpower.

Weeks 9–12: reassess the decision, not compliance

Review what was feasible, how waist, blood pressure, capacity, sleep and glucose changed, and repeat A1C or the test that prompted the plan when appropriate. Keep what can last. Persistent high risk may call for more nutrition support, assessment of apnoea or MASLD, medication review, or treatment for obesity, prediabetes or diabetes according to indication.

Time-restricted eating: a small, specific effect

The 2026 meta-analysis included 11 randomised trials and 602 adults with overweight or obesity. Adding time-restricted eating to exercise, compared with a control diet plus exercise, changed HOMA-IR by −0.44 (95% CI −0.82 to −0.06), body weight by −1.64 kg, fat mass by −1.30 kg and waist circumference by −1.53 cm. Fasting glucose, fasting insulin, A1C, lipids and blood pressure did not differ significantly.

Subgroup analyses of interventions longer than eight weeks showed more favourable signals in selected markers, but these remain subgroup findings. Evidence does not establish that one eating window prevents diabetes or cardiovascular events, or that timing acts independently of lower intake. If the approach fits your preferences, our intermittent-fasting guide explains contraindications and limits.

Berberine, omega-3 and magnesium: what can be recommended

A recommendation should begin with the indication, not the capsule: correcting a deficiency, treating triglycerides, covering insufficient intake or answering a defined clinical question. The 2026 ADA Standards do not recommend routine micronutrients or herbs for glycaemic benefit. If one is considered, record the product, dose, duration, aim and medicines, and change one variable at a time.

Supplement	What the evidence studied	Clinical reading	Risks and limits
Berberine	A meta-analysis of 20 trials and 1,761 participants found HOMA-IR −0.85 (95% CI −1.16 to −0.53), fasting glucose −0.52 mmol/L and A1C −4.48 mmol/mol. Trials used varied products and doses, commonly 0.9–1.5 g/day in divided doses for roughly 8–24 weeks.	A modest signal, strongest in type 2 diabetes and Asian populations. It does not prove diabetes prevention, is not equivalent to metformin and does not support self-treatment for one high HOMA result.	Nausea, diarrhoea or constipation; variable product quality and drug interactions. Avoid during pregnancy and breastfeeding and in infants. Review carefully with glucose-lowering medicines, anticoagulants or other narrow-therapeutic-index drugs.
Omega-3	A 2026 meta-analysis pooled 11 trials in people with diabetes. It found signals in insulin and HOMA-IR but no significant change in A1C, glucose, triglycerides or most other markers; certainty was low or very low. EPA/DHA formulation and dose varied across trials.	It is not an established treatment for insulin resistance. It may have a separate indication—for example triglycerides using a prescribed formulation and dose—or come from fish in the diet, but that answers a different clinical question.	Gastrointestinal effects and aftertaste; review allergy, anticoagulation and antiplatelet use. High doses should be individualised because some cardiovascular trials have signalled more atrial fibrillation.
Magnesium	A 2026 meta-analysis included 15 trials and 1,085 people with diabetes or prediabetes. Neither insulin (−1.73 mU/L; 95% CI −3.73 to 0.27) nor HOMA-IR (−0.74; 95% CI −1.58 to 0.09) improved significantly; splitting trials by ≤250 or >250 mg/day and duration did not change the conclusion.	Correcting hypomagnesaemia, insufficient intake or a defined cause makes sense. Routine use as an “insulin sensitiser” is not supported by this analysis.	Diarrhoea and cramps; accumulation risk with impaired kidney function. It can reduce absorption of levothyroxine, bisphosphonates and some antibiotics unless doses are separated.

These effect sizes cannot be compared directly across products, and a lower HOMA-IR does not prove fewer heart attacks, diabetes diagnoses or deaths. Any therapeutic trial needs a reason, a limited duration, an agreed clinical outcome and a safety review; “just in case” is not a protocol.

Decision table: what changes with the result

Situation	Proportionate next step	What to avoid
Normal glucose and A1C, no important risk factors	Routine prevention; repeat by age and risk, not anxiety	Universal insulin panels, CGM or supplements
Acanthosis, PCOS, MASLD, apnoea, high waist or triglycerides	Assess full phenotype, glycaemia and comorbidity; treat cause and risk	Using HOMA to explain everything
Isolated high HOMA-IR	Check conditions, assay, medication and which decision changes; read trend with the rest of the profile	Self-diagnosing prediabetes or “severe resistance”
A1C 5.7–6.4%, fasting 100–125 or OGTT 140–199 mg/dL	Confirm/classify, use a structured plan and monitor at least yearly; medication only by risk	Waiting for it to “become diabetes” or treating HOMA alone
Diabetes-range result without unequivocal symptoms	Confirm with a second test, classify type and begin clinical care	Trying to fix it first with an extreme diet
Pregnancy or planning pregnancy	Use the specific obstetric pathway and thresholds	Applying non-pregnant population cutoffs
Marked thirst, frequent urination, weight loss, vomiting or abnormal breathing	Prompt testing and urgent assessment; emergency care for persistent vomiting, confusion or breathing difficulty	Waiting eight weeks or relying on a wearable

Risks, medication and red flags

A sudden food reduction or large increase in exercise can cause hypoglycaemia in someone taking insulin or a sulfonylurea. Prolonged fasting is also risky in pregnancy, eating disorders, low body weight, frailty and selected kidney or liver conditions. SGLT2 inhibitors need a specific plan around fasting, surgery and illness because of the uncommon risk of ketoacidosis even without extreme glucose.

Metformin, GLP-1-based therapy, SGLT2 inhibitors and other medicines are selected by diagnosis, cardiovascular and kidney risk, weight, goals, contraindications and preferences; they are not “HOMA treatments”. Supplements also lack interchangeable quality, dose and interaction profiles. The 2026 ADA/EASD consensus does not recommend specific supplements for glycaemic management in type 2 diabetes.

Seek urgent care for persistent vomiting with inability to drink, rapid or deep breathing, confusion, marked dehydration, severe abdominal pain or fruity-smelling breath, especially with diabetes, ketones or SGLT2 treatment. Excessive thirst and urination, unexplained weight loss, blurred vision or repeated infections deserve prompt assessment.

Measure, interpret, then decide again

A continuous glucose monitor without diabetes may support one defined behavioural question, but it does not diagnose insulin action. Likewise, HOMA can add context without becoming an identity. Good medicine integrates the signal with history, tissue, associated disease and time.

At Progevita, the coherent sequence is to listen, measure what is needed, interpret the whole picture, propose a feasible change and reassess. An evaluation can organise glucose, blood pressure, lipids, body composition, movement, sleep and medication without promising to “reverse” one index. If that is the conversation you need, you can start your plan with explicit goals and follow-up.

Frequently asked questions about insulin resistance

At what age can it appear?

At any age. Risk shifts during puberty, pregnancy and ageing and also depends on genetics, body composition, activity, sleep, illness and medication. General glucose screening from age 35 is a prevention recommendation, not an age of onset.

How do I know if I have insulin resistance?

There is no single routine diagnostic test for everyone. History, medication, blood pressure, waist or body composition, glucose, A1C, lipids and sometimes OGTT define the useful picture. HOMA-IR may add context, but has no universal cutoff.

What symptoms does it cause?

Often none. Fatigue, hunger, sleepiness and difficulty losing weight are nonspecific. Acanthosis, PCOS, MASLD, apnoea, high triglycerides or an expanding waist raise suspicion without confirming it.

What is a normal HOMA-IR?

There is no universal value. The 2.93 threshold proposed in a 2026 study modestly identified metabolic syndrome in a selected population with BMI ≥25; it is not a cutoff for every person, laboratory or ethnic group.

Can it exist with normal glucose and A1C?

Yes. The pancreas can compensate with more insulin. That does not make fasting insulin a universal screening test; order it only when context and the decision justify the added uncertainty.

Can a CGM detect it?

No. It measures interstitial glucose, not insulin sensitivity. It can observe responses with error and variability, but no validated diagnostic pattern exists for people without diabetes.

Can insulin resistance be reversed?

It may improve with movement, strength, food, sleep, indicated weight loss and treatment of contributing conditions. “Reversal” should not imply that moving one marker guarantees prevention.

Is intermittent fasting the best treatment?

No. It may suit some people, but the additional average HOMA-IR effect was small and did not significantly change A1C, lipids or blood pressure. Safety and sustainability matter more than a universal window.

Do I need metformin or supplements?

Not because of HOMA-IR alone. Metformin is considered for defined indications and risk profiles. Berberine has a modest but heterogeneous signal; omega-3 is not an established insulin-resistance treatment; and magnesium is prioritised when deficiency or another indication exists. None replaces diagnosis, lifestyle work or an interaction review.

Sources

1. Gastaldelli A et al. Insulin resistance in the 21st century: 2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2026.
2. American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026.
3. American Diabetes Association. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026.
4. Davies MJ et al. Management of type 2 diabetes, 2026: ADA/EASD consensus report. Diabetologia. 2026.
5. NIDDK. Insulin Resistance & Prediabetes.
6. Effects of Time-Restricted Eating Combined with Exercise on Body Composition and Cardiometabolic Health in Adults with Overweight or Obesity: systematic review and meta-analysis. 2026. PMID: 42743072.
7. Frigerio F et al. Capturing metabolic syndrome: new thresholds for insulin resistance and novel body composition indices. International Journal of Obesity. 2026.
8. Zhao JV et al. Overall and sex-specific effect of berberine on glycemic and insulin-related traits: systematic review and meta-analysis. Journal of Nutrition. 2023.
9. Loaiza-Giraldo JP et al. Effectiveness of omega-3 supplementation in patients with diabetes: systematic review and meta-analysis. Current Developments in Nutrition. 2026.
10. Amiri A et al. Oral magnesium supplements and insulin resistance in diabetes and prediabetes: systematic review and meta-analysis. BMC Nutrition. 2026.
11. National Center for Complementary and Integrative Health. Diabetes and dietary supplements: evidence and safety.

Method: narrative review of the linked guidelines, consensus and studies, with Spanish and English search results checked on 7 October 2026. Insulin-sensitivity measurement, glycaemic diagnosis and clinical outcomes are kept separate; an association or HOMA change is not presented as proven prevention. This article is educational and does not replace medical care.